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Abstract 
Altitude is a confounding factor within the Athlete’s Biological Passport (ABP) due, in part, 
to the plasma volume (PV) response to hypoxia. Here, a newly developed PV blood test is 
applied to assess the possible efficacy of reducing the influence of PV on the volumetric ABP 
markers; hemoglobin concentration ([Hb]) and the OFF-score. 
Endurance athletes (n=34) completed a 21 night simulated live high: train low protocol 
(14h.d
-1
 at 3000m). Bloods were collected twice pre-altitude, at days 3, 8 and 15 at altitude 
and 1, 7, 21 and 42 days post-altitude. A full blood count was performed on the whole blood 
sample. Serum was analysed for Transferrin, Albumin, Calcium, Creatinine, Total Protein, 
and Low-Density Lipoprotein. The PV blood test (consisting of the serum markers, [Hb] and 
platelets) was applied to the ABP adaptive model and new reference predictions were 
calculated for [Hb] and the OFF-score, thereby reducing the PV variance component.  
The PV correction refined the ABP reference predictions. The number of atypical passport 
findings (ATPFs) for [Hb] was reduced from 7 of 5 subjects to 6 of 3 subjects. The OFF-
score ATPFs increased with the PV correction (from 9 to 13, 99% specificity); most likely 
the result of more specific reference limit predictions combined with the altitude-induced 
increase in red cell production. Importantly, all abnormal biomarker values were identified by 
a low confidence value. Although the multifaceted, individual physiological response to 
altitude confounded some results, the PV model appears capable of reducing the impact of 
PV fluctuations on [Hb].  
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Introduction 
Rather than the direct detection of a doping substance, the Athlete’s Biological Passport 
(ABP) is focused on the physiological changes resulting from doping practices (i.e., indirect 
detection).
[1]
 However, the ABP relies on a number of concentration-based markers, 
including hemoglobin concentration ([Hb]) and the OFF-score (OFF-score = [Hb] (g/dL) x 10 
– 60 x √reticulocyte%),[2] and plasma volume (PV) fluctuations currently represent the 
majority of biological variation associated with these markers. Recently, PV shifts resulting 
from acute hyper-hydration or an increase in training load have been found to influence an 
ABP profile.
[3,4]
 An alternative scenario where PV shifts occur naturally is during exposure to 
altitude. It is well documented that altitude promotes a natural reduction in PV in the first few 
days of ascent from sea level, reflected by an increase in [Hb].
[5]
 As an athlete adapts to the 
low oxygen environment, red cell production is stimulated and a true increase in hemoglobin 
mass (HbM) is commonly observed.
[6]
 Of note, altitude is especially problematic to the ABP, 
as athletes commonly live and train in hypoxic environments to naturally improve their 
performance, often in the weeks preceding a major competition. Nevertheless, there is 
currently no method in place to correct volumetric ABP markers for such naturally occurring 
PV shifts. 
 
Recently, our laboratory developed a novel method to estimate absolute PV through the 
observed variability of a panel of common biomarkers.
[7]
 This novel marker for PV, requiring 
only a blood test, was suggested as a potential tool to adjust for volume fluctuations 
influencing the concentration-based markers of the ABP.
[8]
 By applying the PV correction to 
the adaptive model of the ABP, the specificity of the resulting reference limit calculations 
were refined.
[8]
 However, before the PV correction can be applied to anti-doping practices, 
validation of the model in a variety of relevant situations is necessary.  
 
Within this study, an attempt is made to reduce the confounding effects of PV shifts at 
altitude with the application of the PV correction to the ABP adaptive model. It is 
hypothesised that altitude will stimulate an initial reduction in PV; however, with the 
application of the PV correction to the ABP adaptive model, this natural fluctuation of PV 
will be accounted for. 
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Methods 
34 sub-elite endurance athletes (19 m, 15 f) with at least 3 years of training history completed 
21 days of simulated LHTL altitude training. Mean ± standard deviation for age and VO2max 
of males and females was 28.1 ± 9.2 years and 65.9 ± 6.6 (ml.kg
-1
.min
-1
) and 29.9 ± 6.3 years 
and 54.2 ± 5.6 (ml.kg
-1
.min
-1
), respectively. Athletes spent on average 14 h per day at a 
simulated altitude (normobaric hypoxia) of 3000 m. All training was conducted at normoxia 
(~600m, Canberra, Australia). Participants were excluded if they showed signs of iron 
overload (hemochromatosis, hemeosiderosis), polycythaemia, iron deficiency, or recently 
received a blood transfusion or donated blood. Baseline hematology and HbM measures 
[9]
 
were collected -14 and -1 day prior to altitude exposure (B1, B2) and then at days 3, 8 and 15 
at altitude (A3, A8, A15) and +1, +7, +21 and +42 days post-altitude (P1, P7, P21, P42). 
Note that HbM was not measured at A3. A schematic diagram of the testing protocol is found 
in Figure 1. As part of a parallel investigation, subjects were split into three iron 
supplementation groups, placebo (no supplementation), oral supplementation or a course of 
intravenous (IV) injections. Details of the iron supplementation protocol 
[10]
 and HbM 
protocol 
[7]
 can be found elsewhere. Venous blood was sampled following strict World Anti-
Doping Agency (WADA) blood collection and analysis protocol.
[11]
 A 3 mL whole blood 
K2EDTA sample (BD vacutainer, Ref 367856, Plymouth United Kingdom) was stored at 
room temperature (21 degrees) and analysed for Hemoglobin concentration ([Hb]), Platelets 
(PLT), Mean Corpuscular Hemoglobin Concentration (MCHC), and Reticulocytes percentage 
(RET%) on a Sysmex XT 2000i (Kobe, Japan) in automatic mode within 24 hours. An 8.5 
mL serum sample (BD vacutainer, Ref 367988, Plymouth, United Kingdom) was collected, 
stored at room temperature for 15 min before centrifugation at 4°C and 1500 rpm for 10 min. 
Serum was aliquoted and stored at -80°C and batch analysed in random order with an 
COBAS Integra 400 (Roche Diagnostics, Switzerland) for the following 6 chemistry 
variables: Transferrin (Tfn), Albumin (ALB), Calcium (Ca), Creatinine (CRE), Total Protein 
(TP), and Low-Density Lipoprotein (LDL). The Australian Institute of Sport human ethics 
committee approved the study and all subjects provided written consent before participating. 
 
Statistics 
A validation of the previously describe PV model is performed here. Detailed descriptions of 
the statistical development of the PV model 
[7]
 and its application to the adaptive model of the 
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ABP paradigm can be found elsewhere.
[8]
 Within the PV model a confidence level is 
associated with the calculated PV Z-score, returned by the model. The confidence level is 
equal to the exponential sum of the weighting function (calculated as a normality probability 
distribution of residuals in the variations of the markers) and is normalized between 0 and 1, 
so that values close to 0 have low confidence while values close to 1 have high confidence. 
The confidence level weights the variance that is used to calculate the Z-score associated to 
PV shifts. Confidence in the PV model prediction is, therefore, related to the uniformity of 
the PV marker Z-scores. 
By applying an adaptive Bayesian model, and the principles of the ABP, a longitudinal 
profile for [Hb] and OFF-score calculations for each individual subject was produced 
(specificities were set at both 99% and 99.9%). The individual [Hb] and OFF-score values 
were entered into the Bayesian model, which produced individualised reference limits. The 
individual estimations of PV, derived from the panel of 8 PV markers ([Hb], Tfn, CRE, Ca, 
PLT, LDL, ALB, and TP) applied to an adaptive model, were then used to correct the 
individual ABP reference calculations for [Hb] and the OFF-score.  
 
Results 
Table 1 quantifies the mean change from baseline levels (using the B2 measure only) in [Hb] 
and PV. The largest PV mean change from baseline occurred at A8 in males (-9.6%) and A15 
in females (-5.3%), calculated from the individual change values from baseline. The largest 
%change from baseline in PV occurred concurrently with the largest %change value in [Hb]. 
The individual PV response to altitude varied, and females presented with more variable 
change values (ranging from -19.7% at A3 to 15.9% at A15) in comparison to males who 
tended to present with PV contractions from baseline levels (ranging from -26.8% at A8 to 
9.0% at P42). 
From a total of 283 observations from 34 subjects the number of Atypical Passport Findings 
(ATPFs) for [Hb] was reduced when the PV model was applied. Without the correction, 7 
ATPFs of 5 subjects (99% set specificity) and 3 of 3 subjects (99.9% set specificity) were 
recorded. This was reduced to 6 of 3 subjects (99% specificity) and 1 (99.9% specificity) 
ATPF with the PV correction (Table 2, the original [Hb] ATPF data are presented 
elsewhere).
[10]
 However the OFF-score recorded an increased number of ATPFs with the 
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inclusion of the PV correction (at a set specificity of 99%). The ATPFs were increased from 
9 of 8 subjects (99% set specificity) without the correction, to 13 of 11 subjects with the 
correction (Table 3). At a 99.9% set specificity, the OFF-score ATPFs were reduced from 4 
of 4 subjects to 3 of 3 subjects. Two values were removed due to high abnormal chemistry 
values resulting from sampling errors (A15 from Subject 24 and P7 from Subject 29).  
Figure 2 (Subject 11) gives an example of the PV models function and describes the expected 
PV contraction at A3, resulting in an increased [Hb]. Subsequent changes in PV were also 
inversely related to [Hb] and the OFF-score. With the inclusion of the PV correction, the 
specificity of the predicted reference ranges for [Hb] and the OFF-score were improved 
(Figure 2, panels A and E, respectively). For example, for Subject 11, at P7 the calculated Z-
scores for PLT, LDL, CRE and Tfn were lower than the remaining four biomarkers (Figure 2, 
panel N), and therefore, the confidence calculation dropped to ~45% for this particular test 
(Figure 2, panel M).  
 
One individual subject (Figure 3, Subject 8) presented with uncharacteristic results whereby 
[Hb] was the only PV biomarker to respond to a PV contraction observed between B2 and 
A8. From B2, A3 and A8 [Hb] increased from 146 to 166 and 176 g/L, respectively. The 
calculated PV decrease (using the CO-rebreathing method) at A3 and A8 was -19.4% and -
26.8%, respectively. This volume shift was not reflected in any of the PV biomarkers. 
Importantly, the confidence in the PV estimation for A3 and A8 was 0%.  
 
Subject 1 (female, IV group) recorded an increase in HbM towards the end of the altitude 
sojourn (Figure 4, panel B), presenting with increases in HbM greater than the female sample 
mean (between 33 to 67%). The increase in HbM was reflected with an increase in [Hb] at 
A15 and P1, which, as expected, was not reflected in any other PV biomarker. This increase 
in [Hb], due to the HbM increase (rather than a PV shift), resulted in a decline the confidence 
to near 0% of the PV calculation.  
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Discussion 
Exposure to hypoxia results in a number of inherent physiological adaptations, which alter an 
athlete’s hematological profile.[12] The volumetric response to altitude is of interest here, and 
specifically, the influence of the initial hemoconcentration on the ABP markers, [Hb] and the 
OFF-score. A maximum mean decrease in PV was observed concurrently with the maximum 
mean increase in [Hb] for both males and females, confirming the initial primary confounder 
of [Hb] fluctuations to be the PV contraction. A few ATPFs were observed for [Hb] and the 
OFF-score values during and post-altitude, most likely the result of the initial PV shift, as 
well as the expected increase in red cell production. Importantly, when the PV correction was 
applied to the adaptive model, the reference limits were refined and the number of ATPFs for 
[Hb] was reduced. However, the number of ATPFs recorded for the OFF-score increased 
with the inclusion of the PV correction (99% set specificity). It has to be highlighted that the 
study setting in this investigation presents a “worst case scenario” to test the functionality of 
the PV model: Indeed, PV is influenced by altitude, but at the same time, HbM will be 
impacted by the hypoxic exposure and the various iron supplementation protocols. While this 
is a possible scenario in certain athletes, the strongest (and most common) modulator of PV 
in a normal setting is exercise alone.
[13]
  
 
A measureable increase in HbM has been reported after just 10 days at altitude,
[14]
 but 
typically does not present until a sufficient hypoxic dose 
[15]
 has been achieved. Therefore, 
the initial PV reduction upon arrival at altitude is most likely the primary factor influencing 
[Hb] fluctuations within the initial stages of altitude exposure.
[16]
 In our investigation, the 
initial hemoconcentration was not observed in all athletes, and there was substantial 
variability in the individual response to altitude (Table 1). Beidleman and colleges also 
described variability in the individual response, where the reported standard error for [Hb] is 
large for the impact of the time spent at altitude (see Table 3 of Beidleman et al),
[5]
 
suggesting considerable inter-individual variability at altitude. Additionally, the intermittent 
nature of the LHTL protocol,
[12]
 differences in training load, 
[17]
 and the non-standardisation 
of blood collection times may have impacted the variable volumetric response reported here. 
Due to scheduling restrictions in the current study, the timing of the blood withdrawals and 
training programs were not standardised. Nevertheless, testing schedules can be random in an 
anti-doping setting, thus reflecting the practical application of the current results.
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Frequency of atypical Passport Findings 
When the PV correction was applied to the ABP adaptive model, the predicted reference 
limits were narrowed and the number of ATPFs for [Hb] was reduced, which supports the 
model. With the PV correction, four subjects no longer recorded ATPFs, however; Subject 1 
and Subject 25 recorded ATPFs only when the PV correction was applied (Table 2). This 
may be a reflection of the additional confounding effects of altitude on the ABP markers, 
namely an increased rate of erythropoiesis, which is reflected in the augmentation of 
reticulocytes.
[18–20]
 Subject 1 (Figure 4) and 25 recorded increases in RET% (which is not 
affected by PV) at A3 and A8, respectively, indicating an increased red cell production 
influencing the [Hb] increase.  
 
On the other hand, the OFF-score recorded an increased rate of ATPFs with the PV 
correction (99% set specificity). The OFF-score is probably more sensitive to the increased 
rates of erythropoiesis at altitude due to the inclusion of RET% in the OFF-score algorithm. 
Therefore, when the PV correction is applied in an altitude scenario, the resulting reference 
limits become too narrow, causing in an increased rate of false positives. However, with 
99.9% specificity the OFF-score ATPFs were reduced by one when the PV correction was 
applied (Table 3). The time between sample collections must also be considered. Blood 
collections acquired in quick succession, such as a few days apart, are at risk of the influence 
of sample autocorrelation and the time between measures was brief within this 
investigation.
[10]
 
 
Overall, applying the PV correction to both [Hb] and the OFF-score was viable in a number 
of individuals who did not present with ATPFs with the inclusion of the PV correction (only 
2% and 5% of the 283 observations were atypical for [Hb] and the OFF-score, respectively). 
However, because of some false positives, further research into the PV correction and its use 
within altitude scenarios is required. 
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The Weighing Function of the PV Model  
The components of biomarker variance were higher than expected in some subjects, which 
resulted in a low confidence in the PV estimation (calculated with the weighting function 
within the PV model algorithm). If the PV correction is to be considered for the ABP it is 
vital that the number of false positive ATPFs is kept to an absolute minimum and not 
increased. An important observation from this investigation was the association between the 
low confidence value and uncharacteristic chemistry values. In a hypothetical anti-doping 
scenario where one or more of the PV biomarkers fluctuate abnormally, resulting in a low 
confidence value, it is recommended that the ABP adaptive model excludes the PV correction 
for this particular observation.  
A few subjects within this investigation recorded PV estimations associated with a low 
confidence value due to non-uniform PV biomarker Z-score calculations. One subject of 
interest (Subject 8, Figure 3) presented with a significant decrease in PV between B2 and A8, 
resulting in an increase in [Hb]. However, no other PV biomarker responded in the same 
manner to this volume shift. Additionally, Subject 8 presented with 3 of the 7 [Hb] ATPFs 
both with and without the addition of the PV correction (Table 2). Subject 8 presented with a 
uniform PV biomarker variance (represented as Z-score calculations) at time points B1 and 
B2, resulting in a confidence calculation of 100%. However, for tests A3, A8 and A15 [Hb] 
increased significantly, due to a PV shift (calculated from the CO-rebreathing technique). 
This PV shift was not reflected in any other PV biomarker, resulting in a decrease in the 
confidence calculation to 0%. For P1 and P42 (Tests P7 and P21 were not performed due to 
subject availability at the required time of testing), the biomarker variance was more uniform, 
and consequently, the confidence in the PV estimation increased. As a result, there was 
disparity between the calculated PV Z-scores using the CO-rebreathing method and PV 
marker method (Figure 3, panel O). In this particular case, the components of the [Hb] 
fluctuation are realistic of a PV shift. The absence of a response from the remaining 7 
volumetric biomarkers of the PV model is disconcerting. However, encouragingly, the 
weighting function within the model identified this disconnect in the biomarker variances, 
and is reflected by the low confidence estimation.  
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Limitations  
Although the present study was performed in accordance to current WADA protocol and 
every effort was made to adhere strictly to the sample collection, handling and analysis 
protocols, it is important to recognise that the data presented here were collected under a 
research setting. For the PV marker to be introduced into anti-doping practices, stringent 
protocols must be developed for the sample collection, handling, analysis, and storage of the 
proposed chemistry markers, similar to those which are in place for the established ABP 
markers such as [Hb] or RET%. Additional factors that were not standardised within this 
investigation include diet, training and the timing of blood withdrawals. Further, the testing 
was performed during the Canberra winter, and a few subjects presented with Upper 
Respiratory Tract Infections. Finally, it must be mentioned that the likelihood of any of the 
subjects doping within this investigation is extremely low, yet cannot be excluded entirely. 
Of relevance however, each subject signed a statutory declaration prior to commencing the 
investigation, stating they have not and will not participate in any doping practices.  
 
Conclusion and practical recommendations 
The results presented here demonstrate the potential of the PV correction to refine the ABP 
reference limit calculations by removing the influence of PV on volumetric markers. It 
appears that the model is able to reduce the number of ATPFs on [Hb] in a reliable manner in 
most subjects. However, the multifaceted, individual physiological response to altitude 
confounded the results for some individuals. Nevertheless, the weighting function allowed an 
assessment of the outcome confidence, and could be included in any possible evaluation of an 
ABP. As such, it is recommended to include the confidence calculation when implementing 
the model, because it allows one to appropriately weight the evidence added by the PV 
correction. This investigation also highlights the importance of further research and 
development into a standardised protocol for the collection, handling, analysis and storage of 
the novel PV biomarkers. 
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Table 1. Observed change values from baseline in hemoglobin concentration and 
plasma volume. 
Study Day [Hb] (g/L) PV (mL) 
Males Mean %Δ (min, max) Mean %Δ (min, max) 
B2 148 ± 7 0 4336.0 ± 707.9 0 
A3 152 ± 8  3.3 (-6, 13.7) 4139.7 ± 760.3  -4.5 (-19.4, 8.7) 
A8 157 ± 8  6.7 (-1.3, 20.6) 3919.1 ± 682.9  -9.6 (-26.8, 1.7) 
A15 157 ± 8  6.7 (0, 19.2) 3999.5 ± 687.9  -7.7 (-22.7, 5.9) 
P1 156 ± 9  5.7 (-1.3, 17.1) 4106.0 ± 725.5  -5.3 (-20.9, 4.2) 
P7 154 ± 8  4.2 (-2.5, 13.9) 4205.8 ± 747.4  -4.9 (-18.9, 6.6) 
P21 152 ± 6  2.2 (-3.4, 8.7) 4205.4 ± 706.5  -2.5 (-11.5, 4.5) 
P42 150 ± 7  1.3 (-3.8, 12.3) 4171.2 ± 748.1  -1.9 (-15.3, 9.0) 
Females Mean %Δ (min, max) Mean %Δ (min, max) 
B2 136 ± 9  0 3162.8 ± 344.9  0 
A3 140 ± 10  3.5 (-6.8, 15.1) 3007.3 ± 479.7  -5.1 (-19.7, 10.6) 
A8 142 ± 7  4.5 (-4.2, 10.1) 3002.1 ± 377.7  -5.1 (-13.5, 8.5) 
A15 144 ± 11  6.3 (-7.6, 18.5) 2993.1 ± 400.7  -5.3 (-18.0, 15.9) 
P1 144 ± 8  5.9 (-2.1, 15.3) 3024.2 ± 455.6  -4.7 (-13.0, 6.2) 
P7 141 ± 7  2.6 (-1.4, 8.5) 3144.7 ± 305.1  -2.4 (-11.1, 7.2) 
P21 138 ± 7  0.4 (-6.1, 8.7) 3199.7 ± 388.5  0.3 (-9.6, 14.4) 
P42 138 ± 7  1.9 (-3.5, 12.2) 3102.5 ± 414.8  -1.4 (-13.0, 11.9) 
 
All placebo subjects (n = 9; 5 M, 4 F) have been removed to reduce the impact of differences 
in the erythropoietic response to altitude influencing [Hb] and thus PV values. 
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Table 2. Atypical passport findings for hemoglobin concentration with and without the 
plasma volume correction 
Subject Test ATPF (upper or 
lower limit)  
Confidence (%) 
Without Correction  
S6 A15 Lower  
S8 A3 Upper  
S8 A8 Upper *  
S8 A15 Upper  
S17 A3 Upper *  
S21 A8 Upper  
S30 A15 Upper *  
With Correction  
S8 A3 Upper 0 
S8 A8 Upper * 0 
S8 A15 Upper 0 
S1 A15 Upper 2 
S1 P1 Upper 0 
S25 P1 Upper 0 
 
(*) Reference limits set at 99.9% specificity were also flagged. Italics indicate subjects who 
recorded an ATPF only when the PV correction was applied. 
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Table 3. Atypical passport findings for the OFF-score with and without the plasma 
volume correction 
Subject Test ATPF (upper or 
lower limit)  
Confidence (%) 
Without Correction  
S1 P7 Upper  
S6 B2 Lower *  
S6 P42 Upper  
S8 A15 Upper  
S13 A15 Upper  
S15 B2 Upper *  
S17 A3 Upper *  
S23 P42 Upper *  
S30 A15 Upper  
With Correction  
S1  P7 Upper * 29 
S6  B2 Lower * 40 
S8  A3 Upper 0 
S8  A15 Upper 0 
S23  P42 Upper * 30 
S5  P1 Upper 5 
S13  P7 Upper 79 
S20  P7 Upper 85 
S20  P21 Upper 100 
S25  P1 Upper 0 
S28 P21 Upper 40 
S30  P1 Upper 2 
S35  B2 Lower 45 
 
(*) Reference limits set at 99.9% specificity were also flagged. Italics indicate subjects who 
recorded an ATPF only when the PV correction was applied. 
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Figure 1. Study design. Baseline HbM calculations (determined by the CO-rebreathing test) 
and blood collection were performed on day -14 and -1 day prior to altitude (B1, B2) 
(represented by the droplet).  Subsequent measures occurred at days 3, 8 and 15 at altitude 
(A3, A8, A15) and +1, +7, +21 and +42 days post altitude (P1, P7, P21, P42). HbM was not 
collected at A3. Subjects received an oral supplement (iron or placebo glucose tablets) daily 
from day -14 to day 21 at altitude and three IV injections (iron or placebo), prescribed at day 
-14, day -1 prior to altitude and day 10 at altitude (represented by the needle).  
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Figure 2. Subject 11. Red lines indicate the ABP adaptive model reference limits set at 99% 
(dashed lines) and 99.9% (solid lines) specificity (panels A, B, D to L). The green reference 
limits for [Hb] (A) and the OFF-score (E) represent the ABP reference limit calculations with 
the inclusion of the PV correction. Panel C shows the red blood cell (RBC) (red line) and 
plasma volume (blue line) values calculated with the CO-rebreathing method. Panel M 
represents the confidence calculation in the PV estimation. Panel N shows the z-scores for 
markers [Hb] (blue), Tfn (red), ALB (yellow), Ca (black), CRE (green), TP (pink), PLT 
(cyan), LDL (dashed blue). Panel O represents the plasma volume z-score calculations using 
the CO-rebreathing method (blue line) and PV model (red line).  
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Figure 3. Subject 8. Refer to Figure 2 for panel descriptions. Note tests P7 and P21 are 
missing. 
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Figure 4. Subject 1. Refer to Figure 2 for panel descriptions. 
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Validation of a blood marker for plasma volume in endurance athletes during a live high: train 
low altitude training camp 
 
Louisa M. Lobigs, Laura A. Garvican-Lewis, Victor L. Vuong, Nicolin Tee, Christopher J. Gore, 
Peter Peeling, Brian Dawson, Yorck O. Schumacher
 
 
 
 
 
 
Altitude is a confounding factor within the Athlete’s Biological Passport (ABP) due, in part, to a 
plasma volume (PV) contraction. Here, a newly developed PV blood test is applied to reduce the 
influence of PV contractions on ABP markers; hemoglobin concentration ([Hb]) and the OFF-score. 
With the PV correction to the ABP reference limits are refined and the number of atypical [Hb] results 
is reduced. The application of the PV correction to the ABP has the potential to improve doping 
detection. 
 
